<p>DAFNA Capital Management LLC 在最近向證券交易委員會（SEC）提交的 13F 文件中表示，在第四季度將其在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免費報告) 的持股比例提高了 9.3%。該基金在此期間購買了額外的 19,000 股後，持有該醫療設備公司 223,208 股股票。Tandem Diabetes Care 佔 DAFNA Capital Management LLC 持有資產的約 2.0%，使其成為該基金第 16 大持股。截至最近向證券交易委員會（SEC）提交的文件，DAFNA Capital Management LLC 持有的 Tandem Diabetes Care 的股份約佔 0.34%，價值 8,040,000 美元。</p>
<p>獲取 <strong>Tandem Diabetes Care</strong> 警報：</p>
<p>其他一些對沖基金最近也增加或減少了對該股票的持股。Hood River Capital Management LLC 在第四季度收購了價值約 46,035,000 美元的 Tandem Diabetes Care 新股份。Brown Advisory Inc. 在第四季度購買了價值 32,889,000 美元的 Tandem Diabetes Care 新股份。Park West Asset Management LLC 在第四季度將其在 Tandem Diabetes Care 的持股比例提高了 49.5%。Park West Asset Management LLC 現在持有 1,600,000 股該醫療設備公司的股票，價值 57,632,000 美元，此前在上個季度又購買了 530,000 股。Baillie Gifford &amp; Co. 在第四季度將其在 Tandem Diabetes Care 的持股比例提高了 235.7%。Baillie Gifford &amp; Co. 現在持有 746,109 股該醫療設備公司的股票，價值 26,875,000 美元，此前在上個季度又購買了 523,843 股。最後，ArrowMark Colorado Holdings LLC 在第四季度將其在 Tandem Diabetes Care 的持股比例提高了 14.1%。ArrowMark Colorado Holdings LLC 現在持有 2,723,715 股該醫療設備公司的股票，價值 98,108,000 美元，此前在上個季度又購買了 337,026 股。</p>
<h2>內部活動</h2>
<p>在其他 Tandem Diabetes Care 的新聞中，首席運營官 Jean-Claude Kyrillos 於 3 月 7 日星期五收購了 10,538 股公司的股票。該股票的平均購買價格為每股 18.12 美元，總交易額為 190,948.56 美元。收購後，首席運營官現在持有 10,538 股公司股票，價值約 190,948.56 美元。此次交易使其持股比例增加了 ∞。該購買在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。公司內部人士持有公司股票的 1.90%。</p>
<h2>Tandem Diabetes Care 股票上漲 4.4%</h2>
<p>TNDM 股票在週四開盤價為 22.26 美元。該股票的市值為 14.8 億美元，市盈率為 -11.53，貝塔值為 1.47。公司快速比率為 2.32，流動比率為 2.90，債務與股本比率為 1.29。該公司有 50 日移動平均線為 18.55 美元，200 日移動平均線為 28.34 美元。Tandem Diabetes Care, Inc. 的 52 周低點為 15.75 美元，52 周高點為 53.69 美元。</p>
<p>Tandem Diabetes Care (NASDAQ:TNDM - 獲取免費報告) 最近於 4 月 30 日星期三公佈了季度財報。該醫療設備公司報告的每股收益（EPS）為 -0.67 美元，低於分析師一致預期的 -0.60 美元，差額為 -0.07 美元。Tandem Diabetes Care 的淨利潤率為 -14.84%，股本回報率為 -44.19%。該公司在本季度的收入為 2.3442 億美元，而分析師預期為 2.2019 億美元。在去年同期，該公司每股收益為 -0.65 美元。與去年同期相比，該公司的收入增長了 22.3%。賣方分析師預測，Tandem Diabetes Care, Inc. 本年度將發佈 -1.68 美元的每股收益。</p>
<h2>分析師評級變動</h2>
<p>一些券商最近對 TNDM 發佈了報告。花旗集團將 Tandem Diabetes Care 的股票評級從 &#34;買入&#34; 下調至 &#34;中性&#34;，並在 3 月 4 日星期二的研究報告中將其目標價從 35.00 美元下調至 24.00 美元。瑞穗證券在 4 月 10 日星期四的研究報告中開始對 Tandem Diabetes Care 進行覆蓋。他們給予了 &#34;中性&#34; 評級，並設定了 20.00 美元的目標價。Piper Sandler 在 5 月 1 日星期四的報告中將 Tandem Diabetes Care 的目標價從 36.00 美元下調至 30.00 美元，並對該股票給予了 &#34;增持&#34; 評級。桑福德·C·伯恩斯坦在 2 月 28 日星期五的報告中將 Tandem Diabetes Care 的股票評級從 &#34;跑贏大盤&#34; 下調至 &#34;市場表現&#34;，並將其目標價從 35.00 美元下調至 25.00 美元。最後，摩根士丹利在 3 月 5 日星期三的報告中將 Tandem Diabetes Care 的股票評級從 &#34;增持&#34; 下調至 &#34;持平&#34;，並將其目標價從 45.00 美元下調至 22.00 美元。八位分析師對該股票給予了持有評級，九位分析師對該公司的股票給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 39.81 美元。</p>
<p><strong>閲讀我們關於 Tandem Diabetes Care 的最新股票報告</strong></p>
<h2>關於 Tandem Diabetes Care</h2>
<p>（免費報告）</p>
<p>Tandem Diabetes Care, Inc. 是一家醫療設備公司，設計、開發並商業化針對美國及國際糖尿病患者的技術解決方案。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送並在泵的主屏幕上直接顯示連續血糖監測傳感器信息的泵平台；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Tandem Diabetes Care</li>
<li>理解看漲期權交易量對成功的期權交易至關重要</li>
<li>DexCom 股票：盈利超預期和新市場準入推動牛市前景</li>
<li>投資中的下調意味着什麼？</li>
<li>優步的財報為股票和更廣泛的經濟提供線索</li>
<li>ETF 會支付股息嗎？你需要知道的事項</li>
<li>機構錯過了反彈：資金流向何處</li>
</ul>
<p><strong>想看看其他對 TNDM 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Tandem Diabetes Care 嗎？</h2>
<p>在考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Tandem Diabetes Care 並不在名單上。</p>
<p>雖然 Tandem Diabetes Care 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TNDM

<p>DAFNA Capital Management LLC 在第四季度將其在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM) 的持股增加了 9.3%，額外購買了 19,000 股，總持股量達到 223,208 股。這項投資約佔 DAFNA 持有資產的 2.0%，價值約為 804 萬美元。其他對沖基金也調整了在 Tandem 的持股。該股票最近上漲了 4.4%，開盤價為 22.26 美元，市值為 14.8 億美元。儘管每股收益未達到預期，Tandem 報告的收入同比增長了 22.3%</p>

<p>DAFNA Capital Management LLC boosted its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,208 shares of the medical device company's stock after purchasing an additional 19,000 shares during the period. Tandem Diabetes Care comprises about 2.0% of DAFNA Capital Management LLC's holdings, making the stock its 16th largest holding. DAFNA Capital Management LLC owned about 0.34% of Tandem Diabetes Care worth $8,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>DAFNA Capital Management LLC 在最近向證券交易委員會（SEC）提交的 13F 文件中表示，在第四季度將其在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免費報告) 的持股比例提高了 9.3%。該基金在此期間購買了額外的 19,000 股後，持有該醫療設備公司 223,208 股股票。Tandem Diabetes Care 佔 DAFNA Capital Management LLC 持有資產的約 2.0%，使其成為該基金第 16 大持股。截至最近向證券交易委員會（SEC）提交的文件，DAFNA Capital Management LLC 持有的 Tandem Diabetes Care 的股份約佔 0.34%，價值 8,040,000 美元。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tandem Diabetes Care</strong> 警報：</p>
</div><p>A number of other hedge funds have also recently added to or reduced their stakes in the stock. Hood River Capital Management LLC acquired a new stake in Tandem Diabetes Care in the fourth quarter valued at approximately $46,035,000. Brown Advisory Inc. bought a new position in shares of Tandem Diabetes Care in the fourth quarter worth $32,889,000. Park West Asset Management LLC grew its stake in Tandem Diabetes Care by 49.5% in the 4th quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock worth $57,632,000 after buying an additional 530,000 shares in the last quarter. Baillie Gifford &amp; Co. lifted its stake in Tandem Diabetes Care by 235.7% in the fourth quarter. Baillie Gifford &amp; Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after purchasing an additional 523,843 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in shares of Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after purchasing an additional 337,026 shares during the last quarter.</p>
<div class="lb-trans"><p>其他一些對沖基金最近也增加或減少了對該股票的持股。Hood River Capital Management LLC 在第四季度收購了價值約 46,035,000 美元的 Tandem Diabetes Care 新股份。Brown Advisory Inc. 在第四季度購買了價值 32,889,000 美元的 Tandem Diabetes Care 新股份。Park West Asset Management LLC 在第四季度將其在 Tandem Diabetes Care 的持股比例提高了 49.5%。Park West Asset Management LLC 現在持有 1,600,000 股該醫療設備公司的股票，價值 57,632,000 美元，此前在上個季度又購買了 530,000 股。Baillie Gifford &amp; Co. 在第四季度將其在 Tandem Diabetes Care 的持股比例提高了 235.7%。Baillie Gifford &amp; Co. 現在持有 746,109 股該醫療設備公司的股票，價值 26,875,000 美元，此前在上個季度又購買了 523,843 股。最後，ArrowMark Colorado Holdings LLC 在第四季度將其在 Tandem Diabetes Care 的持股比例提高了 14.1%。ArrowMark Colorado Holdings LLC 現在持有 2,723,715 股該醫療設備公司的股票，價值 98,108,000 美元，此前在上個季度又購買了 337,026 股。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction on Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Tandem Diabetes Care 的新聞中，首席運營官 Jean-Claude Kyrillos 於 3 月 7 日星期五收購了 10,538 股公司的股票。該股票的平均購買價格為每股 18.12 美元，總交易額為 190,948.56 美元。收購後，首席運營官現在持有 10,538 股公司股票，價值約 190,948.56 美元。此次交易使其持股比例增加了 ∞。該購買在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。公司內部人士持有公司股票的 1.90%。</p>
</div><h2>Tandem Diabetes Care Stock Up 4.4 %</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 股票上漲 4.4%</h2>
</div><p>TNDM stock opened at $22.26 on Thursday. The stock has a market capitalization of $1.48 billion, a PE ratio of -11.53 and a beta of 1.47. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The firm has a 50 day moving average of $18.55 and a 200 day moving average of $28.34. Tandem Diabetes Care, Inc. has a 52 week low of $15.75 and a 52 week high of $53.69.</p>
<div class="lb-trans"><p>TNDM 股票在週四開盤價為 22.26 美元。該股票的市值為 14.8 億美元，市盈率為 -11.53，貝塔值為 1.47。公司快速比率為 2.32，流動比率為 2.90，債務與股本比率為 1.29。該公司有 50 日移動平均線為 18.55 美元，200 日移動平均線為 28.34 美元。Tandem Diabetes Care, Inc. 的 52 周低點為 15.75 美元，52 周高點為 53.69 美元。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same period in the previous year, the firm posted ($0.65) earnings per share. The company's revenue was up 22.3% compared to the same quarter last year. Sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care (NASDAQ:TNDM - 獲取免費報告) 最近於 4 月 30 日星期三公佈了季度財報。該醫療設備公司報告的每股收益（EPS）為 -0.67 美元，低於分析師一致預期的 -0.60 美元，差額為 -0.07 美元。Tandem Diabetes Care 的淨利潤率為 -14.84%，股本回報率為 -44.19%。該公司在本季度的收入為 2.3442 億美元，而分析師預期為 2.2019 億美元。在去年同期，該公司每股收益為 -0.65 美元。與去年同期相比，該公司的收入增長了 22.3%。賣方分析師預測，Tandem Diabetes Care, Inc. 本年度將發佈 -1.68 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of brokerages recently issued reports on TNDM. Citigroup cut shares of Tandem Diabetes Care from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and dropped their price target for the stock from $35.00 to $24.00 in a research note on Tuesday, March 4th. Mizuho began coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a &#34;neutral&#34; rating and a $20.00 price objective for the company. Piper Sandler decreased their price target on Tandem Diabetes Care from $36.00 to $30.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, May 1st. Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their price target for the company from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Morgan Stanley downgraded shares of Tandem Diabetes Care from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and reduced their target price for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $39.81.</p>
<div class="lb-trans"><p>一些券商最近對 TNDM 發佈了報告。花旗集團將 Tandem Diabetes Care 的股票評級從 &#34;買入&#34; 下調至 &#34;中性&#34;，並在 3 月 4 日星期二的研究報告中將其目標價從 35.00 美元下調至 24.00 美元。瑞穗證券在 4 月 10 日星期四的研究報告中開始對 Tandem Diabetes Care 進行覆蓋。他們給予了 &#34;中性&#34; 評級，並設定了 20.00 美元的目標價。Piper Sandler 在 5 月 1 日星期四的報告中將 Tandem Diabetes Care 的目標價從 36.00 美元下調至 30.00 美元，並對該股票給予了 &#34;增持&#34; 評級。桑福德·C·伯恩斯坦在 2 月 28 日星期五的報告中將 Tandem Diabetes Care 的股票評級從 &#34;跑贏大盤&#34; 下調至 &#34;市場表現&#34;，並將其目標價從 35.00 美元下調至 25.00 美元。最後，摩根士丹利在 3 月 5 日星期三的報告中將 Tandem Diabetes Care 的股票評級從 &#34;增持&#34; 下調至 &#34;持平&#34;，並將其目標價從 45.00 美元下調至 22.00 美元。八位分析師對該股票給予了持有評級，九位分析師對該公司的股票給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 39.81 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Tandem Diabetes Care 的最新股票報告</strong></p>
</div><h2>About Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>關於 Tandem Diabetes Care</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc. 是一家醫療設備公司，設計、開發並商業化針對美國及國際糖尿病患者的技術解決方案。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送並在泵的主屏幕上直接顯示連續血糖監測傳感器信息的泵平台；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Uber’s Earnings Offer Clues on the Stock and Broader Economy</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Institutions Skipped the Rally: Where the Money Went</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Tandem Diabetes Care</li>
<li>理解看漲期權交易量對成功的期權交易至關重要</li>
<li>DexCom 股票：盈利超預期和新市場準入推動牛市前景</li>
<li>投資中的下調意味着什麼？</li>
<li>優步的財報為股票和更廣泛的經濟提供線索</li>
<li>ETF 會支付股息嗎？你需要知道的事項</li>
<li>機構錯過了反彈：資金流向何處</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TNDM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 TNDM 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNDM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tandem Diabetes Care 嗎？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Tandem Diabetes Care 並不在名單上。</p>
</div><p>While Tandem Diabetes Care currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tandem Diabetes Care 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

DAFNA 資本管理有限責任公司購入了 Tandem Diabetes Care, Inc.（納斯達克代碼：TNDM）19,000 股股票